Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 10

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 10
---
 v2.0 EYECRYL ARTISAN MPL VISION PRO PRL LOONG CRYSTAL Product(s) NA NA NA Clinical testing in China NMPA approval pending NMPA approval in 2020; next - gen pending NMPA approval in 2025 China Approval LATAM, South America, EMEA, APAC, Australia; and Japan (2025) South America, EMEA, APAC US, LATAM, South America, EMEA, APAC, and Australia CE - marked TBD NA NA Other Markets Key consideration China’s Green Channel regulatory pathway expedites registration for certain medical devices, leading to more local entrants and a rapidly evolving landscape 1. STAAR Management Presentation: Alcon Merger Maximizes Value for Stockholders of STAAR Surgical – September 2025

11 Scaling globally outside China has been (and will likely remain) a challenge for STAAR … Partnering with a strategic is the only viable path to accessing profitable growth 1 1. Alcon estimates 2. From STAAR Sep 2025 “Alcon Merger Maximizes Value for Stockholders of STAAR Surgical” showing - 9.8D average diopter in ’20 to - 9 .4D in ’24 ▪ Untenable global cost structure, limited direct operations (7 markets) ▪ Over - indexed risk in China with s low inroads ex - China (e.g., US) ▪ Pipeline innovation t hat: o Hasn’t been productive in overcoming stalled penetration into myopia 2 (nor providing a path to “break - through” ICLs that could change that trajectory) o Is constrained by STAAR’s P&L and narrow ICL expertise o Has been outpaced by adjacent segments (e.g., LASIK) ▪ Immediate synergies from existing global scale (56 direct markets) ▪ Immediate access to established customer base (e.g., US) ▪ Clear path to “breakthrough innovation” pairing EVO with best - in - class optical designs and Alcon expertise o World - class expertise across technical domains (e.g., optics) o Proven track record of developing / launching innovation “Partner with a strategic” “Go it alone”

12 … and recent cost - cutting activities are more likely to stall sales growth than to accelerate it 1. Forbes, 02 Feb 2024, Shannon Power, https://www.forbes.com/councils/forbesfinancecouncil/2024/02/